前列腺癌男性的长期抑郁与自杀风险:一项全国队列研究
瑞典全国队列纳入1998—2017年确诊前列腺癌的180 189例男性及年龄匹配的1 801 890例对照男性,随访至2018年。高危前列腺癌患者的重度抑郁与自杀死亡相对风险升高,且持续≥10年;单纯雄激素剥夺治疗(ADT)者自杀死亡相对风险更高。作者认为前列腺癌生存者需密切随访以早期发现和处理心理社会困扰。
要点
- 高危前列腺癌患者重度抑郁与自杀死亡的相对风险升高,并持续≥10年。
- 单纯ADT治疗者自杀死亡相对风险更高,放疗或手术者重度抑郁相对风险较低。
- 低/中危患者仅见重度抑郁相对风险轻度升高,自杀死亡仅在确诊后3—12个月升高。
核心结论
- 在这项大型队列中,高危前列腺癌与显著升高的重度抑郁和自杀死亡相对风险相关,且在前列腺癌确诊后持续≥10年。
- 前列腺癌生存者需要密切随访,以及时发现和治疗心理社会困扰。
研究设计与样本
- 瑞典全国队列研究,纳入1998—2017年确诊前列腺癌的180 189例男性,以及1 801 890例年龄匹配、基于人群的对照男性。
- 重度抑郁与自杀死亡通过截至2018年的全国门诊、住院和死亡记录确认,采用Cox回归计算校正社会人口学因素与合并症的风险比(HR)。
- 亚组分析评估2005—2017年前列腺癌治疗方式间的差异。
主要发现
- 高危前列腺癌患者重度抑郁的相对风险升高(校正HR [aHR] 1.82,95%CI 1.75—1.89),自杀死亡的相对风险升高(aHR 2.43,95%CI 2.01—2.95)。
- 上述关联在前列腺癌确诊后≥10年仍持续存在。
- 与单纯ADT(aHR 2.02,95%CI 1.89—2.16)相比,放疗(aHR 1.44,95%CI 1.31—1.57)或手术(aHR 1.60,95%CI 1.31—1.95)者重度抑郁的相对升高较低;自杀死亡相对率仅在单纯ADT治疗者中升高(aHR 2.83,95%CI 1.80—4.43)。
- 低/中危前列腺癌患者重度抑郁相对风险轻度升高(aHR 1.19,95%CI 1.16—1.23),自杀死亡在确诊后3—12个月相对风险升高(aHR 1.88,95%CI 1.11—3.18),但整个随访期未升高(aHR 1.02,95%CI 0.84—1.25)。
临床怎么用
- 作者认为前列腺癌生存者需要密切随访,以及时发现和治疗心理社会困扰。
局限性
- 本研究仅限于瑞典,需要在其他人群中重复验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A diagnosis of prostate cancer (PC) may cause psychosocial distress that worsens quality of life; however, long-term mental health outcomes are unclear. OBJECTIVE: To determine the long-term risks of major depression and death by suicide in a large population-based cohort. DESIGN, SETTING, AND PARTICIPANTS: This was a national cohort study of 180 189 men diagnosed with PC during 1998-2017 and 1 801 890 age-matched, population-based, control men in Sweden. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Major depression and death by suicide were ascertained from nationwide outpatient, inpatient, and death records up to 2018. Cox regression was used to compute hazard ratios (HRs) adjusted for sociodemographic factors and comorbidities. Subanalyses assessed differences by PC treatment during 2005-2017. RESULTS AND LIMITATIONS: Men diagnosed with high-risk PC had higher relative rates of major depression (adjusted HR [aHR] 1.82, 95% confidence interval [CI] 1.75-1.89) and death by suicide (aHR 2.43, 95% CI 2.01-2.95). These associations persisted for ≥10 yr after PC diagnosis. The relative increase in major depression was lower among those treated with radiation (aHR 1.44, 95% CI 1.31-1.57) or surgery (aHR 1.60, 95% CI 1.31-1.95) in comparison to androgen deprivation therapy (ADT) alone (aHR 2.02, 95% CI 1.89-2.16), whereas the relative rate of suicide death was higher only among those treated solely with ADT (aHR 2.83, 95% CI 1.80-4.43). By contrast, men with low- or intermediate-risk PC had a modestly higher relative rate of major depression (aHR 1.19, 95% CI 1.16-1.23) and higher relative rate of suicide death at 3-12 mo after PC diagnosis (aHR 1.88, 95% CI 1.11-3.18) but not across the entire follow-up period (aHR 1.02, 95% CI 0.84-1.25). This study was limited to Sweden and will need replication in other populations. CONCLUSIONS: In this large cohort, high-risk PC was associated with substantially higher relative rates of major depression and death by suicide, which persisted for ≥10 yr after PC diagnosis. PC survivors need close follow-up for timely detection and treatment of psychosocial distress. PATIENT SUMMARY: In a large Swedish population, men with aggressive prostate cancer had higher long-term relative rates of depression and suicide.
引用
- Crump C, Stattin P, Brooks JD, et al. Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study. Eur Urol. 2023. PMID: 37169640. doi:10.1016/j.eururo.2023.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。